2026-11-11 · 2026-11 / week-2

Sally Beauty’s modest FY27 guide meets a reported 20% short float; the short still fails 10/5

Sally Beauty’s modest FY27 guide meets a reported 20% short float; the short still fails 10/5

  • Published: November 11, 2026, 01:06 Singapore time
  • Decision: Reject / no trade
  • Scope: U.S.-listed common stocks, short opportunities only

Summary: Sally Beauty’s FY2027 plan implies about 1.5% sales growth and 1–2% comparable-sales growth. Fourth-quarter free cash flow fell 39.9% year over year, but the next-year guide is only 4.8% below FY2026 while adjusted EPS guidance rises 8.2%. At the latest verified regular-session reference of $19.79, the stock is about 8.8 times the midpoint of issuer adjusted EPS guidance. The short has no 10% base decline, and a 19.73% reported short float plus a reported premarket spike makes a squeeze path credible. The short-interest figure is dated, the premarket print is unverified, and neither supports an executable trade. [1][4][5][8]

Opportunity Ranking

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Sally Beauty (SBH) Short screen FY27 sales midpoint implies roughly 1.5% growth; Q4 FCF fell sharply, while full-year FCF guidance is nearly flat and adjusted EPS rises. The current price implies about 8.8× FY27 adjusted EPS midpoint. [1][2][4] Q4 and FY27 guidance released Nov. 10; transcript copy read in this run. FY27 Q1 guide and holiday demand; exact next report date not verified. Latest displayed FINRA-settled data: 19.73% of float short and 12.22 days to cover as of Oct. 15; not live borrow. [5] Reject: modeled base is flat; bottom stress is +13.7% for the underlying; no 10% base decline. Current regular-session reference available, but spread, depth, locate, borrow and exit capacity are not. Buybacks and positive operating trends can support EPS and price; high reported short interest can amplify a squeeze.
2 Sea Limited (SE) Short screen Q3 consolidated credit-loss provision rose 82.3%, versus 60.0% loan growth; 90-day NPLs rose to 1.3% from 1.1%. Group revenue and net income also grew strongly. [9] Nov. 10 issuer release. First regular-session response and following credit-quality disclosure. Latest displayed short interest was 1.47% of float as of Oct. 15, not current borrow. [11] Reject: no supported 10% base decline or evidence-backed adverse bound. Intraday quote is reference-only; no execution evidence. The provision is consolidated, not a matched-vintage Monee loss rate; strong growth and low reported short interest oppose the short. [9][10][11]
3 TransDigm (TDG) Short screen Q4 GAAP net income fell 4%, but sales rose 23%, organic sales rose 14%, and adjusted EPS rose 15%. FY27 guidance calls for further growth. [12][13] Nov. 10 issuer release. FY27 guidance and the next reported quarter; exact next date not verified. Current borrow and positioning not verified. Reject: the earnings decline alone does not establish a 10% base drawdown. Nov. 9 close is a pre-result reference; no post-result close yet. Strong organic growth, higher guidance and durable aftermarket demand can sustain the valuation.
4 SPDR S&P 500 ETF (SPY), broad-market control Short control The market was down during the session while SBH was above its prior close; this is relative-price context, not an issuer-specific short thesis. [14] Nov. 10 intraday snapshot. None specific to SBH. Broad-market positioning not assessed. Not a candidate: no company-specific disagreement or modeled 10/5 case. Liquid reference instrument; no trade proposed. Broad market reversal can dominate any single-company view.

Selected opportunity: SBH for information value only. It has the freshest short-side evidence and the clearest cash-versus-EPS test; no tradable short is selected.

Why this one now: The Nov. 10 release gives a new annual cash guide and an earnings-call explanation of why management expects BSG to return to growth. The price moved sharply in premarket reports, opened below the prior close, and recovered during the regular session. Those are distinct observations, not proof of short covering. [1][2][3][4][8]

What should surprise the reader: A 39.9% drop in quarterly free cash flow sounds like a broken cash engine. The company’s FY27 FCF guide is about $200 million versus FY26’s $210.1 million, a 4.8% decline, while midpoint adjusted EPS guidance rises 8.2%. The guide assumes that half of FCF goes to repurchases, so some per-share growth depends on capital allocation rather than faster sales. [1][2]

Archive audit: No standalone SBH article or signal was found in the current archive. Sea’s Q3 credit-loss evidence already appears as a comparison in the Nov. 10 ONON article, so it remains a ranking row rather than a second Sea article. [15]

Why This Can Move More Than 5% Soon

The event has already produced a wide, unsettled price path. SBH closed at $19.49 on Nov. 9 after rising 6.44% that session. A Reuters-sourced Investing.com report published at 9:26 a.m. ET on Nov. 10 reported a $21.50 premarket mark, 10.31% above that close. ChartExchange separately showed $19.50 at 9:06 a.m. premarket and a regular-session open of $18.82. At 11:58 a.m. ET, StockAnalysis showed $19.79 with an $18.31–$20.46 range. The timestamps and vendors differ; the $21.50 report is not a regular-session trade or an executable reference. [3][4][8]

The later StockAnalysis regular-session range was about 10.9% of the $19.79 reference. That clears only the discovery screen. It does not give a short a 10% base decline or bound a squeeze to 5%.

10/5 Asymmetry Gate

The reference is the $19.79 regular-session quote at 11:58 a.m. ET on Nov. 10, not an entry. [1][4] The scenario map below applies assumed valuation multiples to the issuer’s FY27 adjusted EPS midpoint of $2.25. The 7.5× and 10× cases are sensitivities, not sourced fair values or historical valuation boundaries. Probabilities are subjective judgments, not market-implied or calibrated frequencies.

  • Highest-probability base move: $19.79, or 0.0% for a short. It fails the required 10% underlying decline.
  • Bottom-case adverse move: $22.50, or +13.7% for the underlying. That fails the +5% adverse limit. The latest short-interest report and the unverified premarket spike support squeeze risk, but do not cap it.
  • Top-case reward versus bottom-case risk: ($19.79 − $16.875) / ($22.50 − $19.79) = 1.08:1, below 2:1. Base-case reward divided by adverse risk is 0:1.
  • Probability-weighted short value: expected terminal price is $19.885; the gross short return is about −0.5% before borrow, spread, slippage, fees or carrying costs.
  • Protection: No evidence bounds losses to 5%. A stop cannot prevent an overnight gap, halt, borrow recall or poor exit.

This is Reject / no trade, not Watchlist economics. The failure holds before costs. Unknown borrow and execution costs make the result worse, not better.

What Should Surprise the Reader

The Q4 release is weak on sales but not uniformly weak on earnings or cash. Net sales rose 0.6% to $952.5 million and comparable sales rose 0.9%. GAAP diluted EPS was $0.60, up 22%; adjusted EPS was $0.62, up 13%. Adjusted operating margin expanded 60 basis points to 10.0%. The Sally Beauty segment grew sales 1.6% with 2.0% comps; Beauty Systems Group sales fell 0.8% with comps down 0.6%. [1]

The cash warning is real. Q4 operating cash flow was $75.1 million and FCF was $46.9 million; the issuer says quarterly FCF declined 39.9% year over year. The full-year figures were $322.6 million of operating cash flow and $210.1 million FCF. FY27 guidance is about $200 million FCF. This is a lower annual cash guide, not evidence that annual FCF has already collapsed. [1]

The earnings-call transcript adds the strongest counterparty case. Management reported a fifth consecutive quarter of comparable-sales growth, said BSG should return to growth, and described ongoing inflation in labor, rent and transportation alongside continued investment in Happy Beauty, marketplaces and Sally Ignited. These are issuer statements, not independently verified demand forecasts. The company says the Fuel for Growth program ended after delivering its targeted savings; whether those savings persist while investment rises is still a test. [2]

The Setup

The short case is that a mature beauty retailer with approximately 1–2% comparable-sales growth should not receive a higher earnings multiple when quarterly FCF has fallen and BSG remains weak. That is a defensible concern. The counterweight is the price and capital structure: the latest quote is 8.8× the FY27 adjusted EPS midpoint, annual FCF guidance is close to FY26, management expects BSG to return to growth, and the reported short float is high. [1][2][4][5]

This is a fresh issuer-specific evidence boundary: the Q4 release gives the first FY27 cash/EPS pairing, while the same-day price path tests the reaction. The earlier November 9 close is not the execution price, and this article does not claim that the premarket move represents a settled market view.

The Market Price

StockAnalysis labels its Nov. 10 11:58 a.m. ET quote as market-open: $19.79, up $0.30 or 1.54% from the Nov. 9 close of $19.49. Its intraday row gives an $18.35 open, $20.46 high, $18.31 low and 685,524 shares. ChartExchange’s earlier 11:29:55 a.m. ET row showed $19.84, with a different $18.82 open, $20.42 high, $18.76 low and 608,558 shares. I use the later StockAnalysis price and its own range; I do not average the feeds. The market had not closed after the release. [3][4]

SPY was $747.83 at 11:35:05 a.m. ET, down 0.65% from its Nov. 9 close of $752.69. SBH was 1.54% above its own prior close at the later 11:58 observation. The snapshots are 23 minutes apart, so this is relative-price context, not a paired intraday-return study. [4][14]

At $19.79, SBH is 8.80× the $2.25 midpoint of FY27 adjusted EPS guidance. A 10% decline to $17.81 would imply 7.92× that midpoint. These are forward non-GAAP multiples; they do not establish intrinsic value and should not be compared directly with a GAAP trailing P/E.

The Mispricing

The market’s challenge is not “sales are flat, therefore short.” FY27 sales guidance of $3.77–$3.81 billion has a $3.79 billion midpoint, about 1.5% above FY26 sales of $3.735 billion. Comparable-sales guidance is 1–2%. That is slow, but not contraction. Adjusted EPS guidance of $2.20–$2.30 has a $2.25 midpoint, up 8.2% from FY26 adjusted EPS of $2.08. FCF guidance is approximately $200 million, 4.8% below FY26. The adjusted EPS outlook assumes 50% of FCF is used for share repurchases. [1]

One secondary estimate snapshot puts Q4 adjusted EPS at $0.62 versus $0.60 expected and sales at $952.5 million versus $950.1 million. That is a modest beat, not a large surprise. The forecast source is a single aggregator snapshot, not a complete consensus distribution. [7]

The price may be too forgiving if buybacks are doing more work than store productivity, BSG fails to return to growth, or the $200 million FCF guide proves optimistic. But the current price does not demand a growth multiple: its roughly 8.8× forward adjusted EPS sensitivity leaves limited room to claim that a 10% decline is the most likely outcome without a new earnings or cash reset. The available evidence identifies a debate, not an attractive short mispricing. [1][2][4]

The Positioning

ChartExchange’s latest displayed official short-interest row is for the Oct. 15 settlement: 18.22 million shares short, 19.73% of its 92.34 million-share float, and 12.22 days to cover. The reported position was down 1.72% from Sept. 30. This is a dated settlement snapshot, not a live short balance, borrow rate, locate or recall measure. FINRA distinguishes reported short interest from daily short-sale volume; neither should be treated as current borrow availability. [5][6]

A high reported short float can magnify a positive result, but price action alone cannot identify forced covering. I found no current options/dealer exposure, fund flows, beneficial ownership changes, borrow cost, locate availability, recall terms or venue-level liquidity. Positioning is partly observed and partly unknown.

The Catalyst

  1. FY27 Q1 execution: Management’s first-quarter guide is $945–$955 million of sales, 0.5–1.5% comparable-sales growth and $0.48–$0.52 adjusted EPS. The report date was not verified. Test comps, segment mix, gross margin and cash conversion against that guide. [1]
  2. BSG return to growth: The CEO said the company expects BSG to return to growth during FY27. The cheapest falsification test is the next segment disclosure: positive comparable sales and improving transactions would weaken the short case. [2]
  3. Cash and repurchases: FY27 FCF is guided at about $200 million, with half expected to fund repurchases. Reconcile actual repurchases, share count and FCF in the next filing. Do not treat authorization or guidance as completed cash use. [1]
  4. Holiday demand: Management said it would test increased marketing for Happy Beauty into the holiday season and was unsure whether salon customers would add discretionary treatments. This is an observable near-term demand test, not a firm catalyst date. [2]

The Payoff

The scenario map uses the FY27 adjusted EPS midpoint because the issuer provides a range and the market price can be translated into a multiple. The same $2.25 EPS input is used in all three cases so the price outcomes isolate valuation sensitivity; it does not assume the guidance is achieved with certainty. [1][4]

  • The top case applies 7.5×, a 15% compression from the current 8.80×, if growth and cash disappoint.
  • The base case keeps the current 8.80× multiple; it assumes neither a new earnings break nor a rerating.
  • The bottom case applies 10×, about 14% above the current multiple, if BSG recovers and short covering extends. The reported $21.50 premarket level was not accepted in the regular session, but it shows why a +5% adverse cap is not defensible. [3][4][8]

The 20% / 55% / 25% weights reflect judgment about those paths. No historical calibration or options-implied distribution is available. With a flat base and a +13.7% adverse case, expected-value arithmetic cannot satisfy the required 10/5 hurdle even before execution costs.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Horizon Conditions Evidence Quality
Top Case 20% $16.88 (7.5× $2.25 adjusted EPS) +14.7% short gross return 12 months, through the FY27 operating and cash test Sales and BSG trends disappoint; market applies a lower multiple. Low; multiple is a desk assumption.
Base Case 55% $19.79 (current reference; 8.80× $2.25) 0.0% Same horizon Slow growth continues, but EPS and cash guidance are broadly delivered and the multiple is unchanged. Low to medium; issuer guide is fresh, valuation multiple is assumed.
Bottom Case 25% $22.50 (10× $2.25 adjusted EPS) -13.7% short gross return Same horizon BSG improves, FY27 guide holds, and short covering supports a modest rerating. Low; multiple is a desk assumption, squeeze is not quantified.
Invalidation n/a New FY27 filing and current price map n/a Next quarterly report; exact date unverified Rebuild the screen if two consecutive quarters show negative comps or FY27 FCF guidance is cut by at least 10%. Medium for observed results; low for future price response.
  • Probability-weighted expected value: $19.885 per share, or about −0.5% gross short return before costs.
  • Current market level and timestamp: $19.79, regular-session intraday reference, Nov. 10, 2026, 11:58 a.m. ET.
  • Primary instrument: Common stock only, if a future independent review ever qualifies it.
  • 10/5 favorable base move: 0.0%; the required base decline is at least 10%.
  • 10/5 credible adverse move: +13.7% underlying in the modeled bottom case; not a maximum-loss bound.
  • 10/5 measurement basis: Reference-only, not a verified entry.
  • 10/5 status: Reject.
  • Confidence: Low. Fresh issuer evidence is available, but scenario multiples and probabilities are subjective, reported positioning is stale, and execution data is missing.

The Kill Shot

The strongest counterparty case is that Sally’s business is stabilizing rather than deteriorating. It posted a fifth consecutive quarter of positive comps, e-commerce grew, adjusted operating margin expanded, and management expects BSG to return to growth. Annual FCF is projected near FY26’s level while EPS rises. Net debt leverage was 1.4× at year-end, cash was $158 million and there were no borrowings under the ABL facility. The company also repurchased $42 million of shares in Q4 and $113 million for FY26. Those issuer-reported facts can support a low multiple and reduce the chance of a forced financing event. [1][2]

The load-bearing assumption in a short is that the weak sales guide and Q4 FCF decline signal a fresh deterioration, not a retailer investing through a modest recovery. The annual cash guide and EPS outlook do not prove the bull case, but they do not support a 10% base decline either.

What Could Go Wrong

  • Guidance uses adjusted, non-GAAP EPS and FCF; reconciliations and actual results may differ.
  • Repurchases may support per-share metrics while consuming cash, and the announced 50% allocation is forward-looking.
  • The Oct. 15 short-interest snapshot is stale; current borrow, locate, cost and recall risk are unknown.
  • The $21.50 premarket mark is a secondary report not independently verified against an exchange print. It is not a fair value or an entry.
  • The regular-session quote and daily range differ slightly across providers. The market was still open; no post-result close had formed.
  • Promotional intensity, labor, rent, transport costs and discretionary salon spending can change margins and demand.
  • A gap, halt, borrow recall or thin exit can exceed the modeled stress. A stop does not cap short losses.

What Would Prove This Screen Wrong

The current conclusion is that no short qualifies, not that the operating risks are false. Revisit the screen if two consecutive quarters show negative comparable sales or if management cuts FY27 FCF guidance by at least 10%. Those are this desk’s review triggers, not company thresholds. Rebuild price, probabilities, borrow and downside at that time. Stronger execution would leave the short rejected.

Risk Audit

Risk Treatment
Q4 FCF fell 39.9% Compare it with FY26 FCF and FY27’s roughly $200 million guide; do not annualize one quarter.
EPS grows faster than sales Guidance assumes 50% of FCF is returned through repurchases; reconcile actual share count and cash use.
Short float near 20% Use the Oct. 15 settlement only as stale positioning context; it is not locate or borrow evidence.
Premarket spike Keep the Reuters-sourced $21.50 report separate from regular-session prices; it is neither accepted nor executable.
Reference quote Entry remains null until a current quote and all short execution gates are independently verified.
Scenario assumptions Multiples and weights are low-confidence sensitivities, not fair value, hard bounds or calibrated frequencies.
Gap and exit risk A stop cannot cap a short through a gap, halt, recall or unavailable liquidity.

Best Trade Strategy

No trade. Do not short SBH from the $19.79 reference or treat the $21.50 premarket report as an entry. No options, leverage, margin, market orders or price-floor logic. Reconsider only after a new operating/cash disclosure and a fresh price map produce a base decline of at least 10%, an evidence-backed adverse case no worse than +5%, at least 2:1 gross reward to adverse risk, and positive expected value after borrow and execution costs. Current locate, borrow, spread, depth, venue quality, volume quality and exit capacity are not verified.

Sources

  1. Sally Beauty Q4 and FY2026 results and FY2027 outlook, SEC Exhibit 99.1, Nov. 10 - primary release filed with the SEC; segment results, cash, repurchases, leverage and guidance.
  2. Sally Beauty Q4 FY2026 earnings-call transcript - third-party transcript copy; management statements are attributed, not independently verified.
  3. SBH intraday and historical prices, ChartExchange - regular-session Nov. 10 quote and Nov. 9 close; the selected observation is 11:29:55 a.m. ET.
  4. SBH historical prices, StockAnalysis / S&P Global Market Intelligence - later 11:58 a.m. ET intraday quote and range used as the reference.
  5. SBH official short-interest table, ChartExchange - latest displayed Oct. 15 settlement, share count, float and days to cover.
  6. FINRA: Short Interest – What It Is, What It Is Not - distinction between settled short-interest data and short-sale volume.
  7. Sally Beauty Q4 2026 earnings summary, MarketBeat - one secondary estimate snapshot; not a full consensus distribution.
  8. Reuters-sourced SBH premarket reaction report, Investing.com, Nov. 10 - reports a $21.50 premarket mark at 9:26 a.m. ET; not independently confirmed as an exchange execution.
  9. Sea Limited Q3 2026 results, Business Wire release reproduced by Stockwatch, Nov. 10 - issuer-released revenue, credit provision, loans, NPLs and share-repurchase authorization.
  10. SE intraday and historical prices, ChartExchange - Nov. 10 regular-session reference and prior close.
  11. SE official short-interest table, ChartExchange - latest displayed Oct. 15 settlement.
  12. TransDigm FY2026 Q4 and year-end results, SEC Exhibit 99.1, Nov. 10 - primary release, organic sales, adjusted EPS, net income and FY27 guide.
  13. TDG historical prices, Yahoo Finance - Nov. 9 regular close; pre-result reference.
  14. SPY intraday and historical prices, ChartExchange - Nov. 10 intraday context and Nov. 9 close.
  15. ONON Q3 no-trade screen, Nov. 10 - current-week archive entry that already includes Sea’s credit-loss result as a candidate comparison.

Research Quality Scorecard

Criterion Score Evidence and deduction
Market disagreement 3/5 Weak sales guidance and Q4 cash decline conflict with EPS and annual cash guidance; no 10% base short is demonstrated.
Evidence base 4/5 Fresh SEC release and live regular-session reference; call transcript is third-party and some quote data conflicts.
Positioning and flows 3/5 Official short interest is high but dated; borrow, ownership and forced flows are unknown.
Catalyst path 4/5 FY27 Q1 and cash guidance are measurable; exact report date is unverified.
Payoff architecture 2/5 Transparent model assumptions; flat base, adverse stress above 5%, gross ratio below 2:1.
Invalidation discipline 4/5 Comp, segment and FCF review triggers are explicit.
Differentiated insight 4/5 The Q4 FCF drop is much larger than the annual cash-guide reduction; buyback assumptions help explain the EPS/cash gap.
Client value 5/5 The screen separates real operating risk from a short setup that can still squeeze.
Total 29/40 Research quality is not trade quality. The failed 10/5 gate requires Reject / no trade.

Bottom Line

Sally Beauty’s modest growth guide and Q4 cash decline deserve monitoring. They do not support a 10% base decline from a stock priced at about 8.8× FY27 adjusted EPS midpoint, especially with nearly one-fifth of the reported float short and no verified borrow. The result is Reject / no trade; the next useful test is whether FY27 comps, BSG growth and FCF meet the guide. [1][4][5]

AI Illustration Prompt

Create a quiet editorial still life of two ledgers on a retail counter. One ledger shows a sharply falling quarterly cash-flow line; the second shows a nearly flat annual cash plan beside a share-repurchase receipt and a small earnings-per-share rise. Behind them, a morning market screen shows a premarket spike fading before the opening bell. Use cream paper, graphite, muted navy and one restrained amber accent. No corporate logos, ticker symbols, price labels or trading instruction. Add a subtle readable “The Mispricing Desk” watermark at lower right.